Dr. Carey Discusses Findings From the CALGB40502 Trial in TNBC

Lisa A. Carey, MD
Published: Wednesday, Feb 07, 2018



Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses findings from the CALGB 40502/NCCTG N063H trial in triple-negative breast cancer (TNBC).

This phase III randomized trial of patients with HER2-negative breast cancer enrolled 799 patients to receive paclitaxel, nab-paclitaxel (Abraxane), or ixabepilone—and most patients also received concurrent bevacizumab (Avastin; 98%). Improvements in overall survival (OS) and progression-free survival were seen with nab-paclitaxel compared with standard paclitaxel for patients with metastatic TNBC. The median OS with nab-paclitaxel was 21.0 months compared with 15.3 months with standard paclitaxel, representing a 26% reduction in risk of death with the hazard ratio of 0.74 (95% CI, 0.51-1.07).

In a subset analysis, an interaction was observed in the clinical subtype where the difference between nab-paclitaxel and paclitaxel varied. In TNBC, nab-paclitaxel outperformed paclitaxel, and the opposite was true for patients with hormone receptor-positive/HER2-negative breast cancer. This data is intriguing and hypothesis generating, Carey says, and it is something to be aware of when looking at other studies of this type.
 


Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses findings from the CALGB 40502/NCCTG N063H trial in triple-negative breast cancer (TNBC).

This phase III randomized trial of patients with HER2-negative breast cancer enrolled 799 patients to receive paclitaxel, nab-paclitaxel (Abraxane), or ixabepilone—and most patients also received concurrent bevacizumab (Avastin; 98%). Improvements in overall survival (OS) and progression-free survival were seen with nab-paclitaxel compared with standard paclitaxel for patients with metastatic TNBC. The median OS with nab-paclitaxel was 21.0 months compared with 15.3 months with standard paclitaxel, representing a 26% reduction in risk of death with the hazard ratio of 0.74 (95% CI, 0.51-1.07).

In a subset analysis, an interaction was observed in the clinical subtype where the difference between nab-paclitaxel and paclitaxel varied. In TNBC, nab-paclitaxel outperformed paclitaxel, and the opposite was true for patients with hormone receptor-positive/HER2-negative breast cancer. This data is intriguing and hypothesis generating, Carey says, and it is something to be aware of when looking at other studies of this type.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x